Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

Summary

Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic hepatitis C (HCV) genotype 1 (GT1) infection

Timeline

Start

2018-06-26

Primary completion

2019-01-08

Completion

2019-06-07

Drugs

Indications